Sagent Pharmaceuticals, Inc. has launched leucovorin calcium for injection, a folic acid derivative, and an adjuvant in antineoplastic agent therapy, in four latex-free and preservative-free vial presentations. According to IMS, for the 12 months ending June 2012, the US market for Leucovorin Calcium for Injection approximated $14 million.

As with all products in Sagent's portfolio, Leucovorin features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

"Leucovorin, which has consistently been on both the American Society of Health System Pharmacists and Food and Drug Administration lists of drug shortages, is one of the first products which we will launch from our supply agreement with Zydus Cadila," stated Jeffrey Yordon, president, chief executive officer and chairman of the Board of Sagent. "We are excited to provide this important product to our customers."

Leucovorin Calcium for Injection is indicated for rescue after high-dose methotrexate therapy in osteosarcoma; to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists; in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible; and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.